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Human somatic cells can be reprogrammed into induced pluripotent stem cells (hiPSCs) with wide lineage
differentiation potential in culture. However, reprogramming and long-term culture can also induce abnor-
malities in these pluripotent cells. This minireview discusses recent studies that have identified changes in
imprinted gene expression and erosion of X chromosome inactivation in female hiPSCs and how under-
standing the sources and consequences of epigenetic variability in hiPSCs will impact disease modeling
and clinical application in the future.The ability to reprogram human somatic cells to an early embry-
onic state, known as induced pluripotent stem cell (iPSC) reprog-
ramming, is a relatively new and powerful technology that allows
researchers to easily generate large numbers of cells with the
potential to differentiate into a wide range of cell types (Takaha-
shi et al., 2007; Yu et al., 2007). Recently, the application of
patient-derived hiPSCs for pharmacologic testing of chemical
compounds in models of human disease, including long QT
syndrome (Itzhaki et al., 2011), RETT syndrome (Marchetto
et al., 2010), and Machado-Joseph disease (Koch et al., 2011),
has been reported. Reprogramming results in a pluripotent
phenotype that is believed to be largely identical to that of
embryonic stem cells isolated from human embryos (hESCs).
This view is supported by studies investigating their differentia-
tion potential in culture and in teratoma formation assays.
Although some genetic and epigenetic differences between
hESCs and hiPSCs had been previously described (reviewed in
Panopoulos et al., 2011), the potential repercussions for subse-
quent applications of iPSCs remained unclear. Recent studies
have further characterized gene expression and epigenetic
patterns of hiPSC lines in unprecedented detail. In this minire-
view, I will discuss these recent investigations, which reveal
frequent aberrations in genomic imprinting and X chromosome
inactivation (XCI), and their potential impact on the future appli-
cation of hiPSC lines (Anguerra et al., 2012; Mekhoubad et al.,
2012; Nazor et al., 2012). This brief review is not intended to be
a comprehensive assessment of gene imprinting or XCI, and
we refer readers to other, more complete reviews on these topics
here (Augui et al., 2011; Ferguson-Smith, 2011).
Epigenetic Differences in hiPSCs
To examine the extent of epigenetic differences in hiPSCs and
the potential impact for their use, Nazor et al. recently investi-
gated gene expression and DNA methylation patterns in a set
of over 200 hESC and hiPSC lines (Nazor et al., 2012). From
these data, two groups of genes with reciprocal epigenetic
patterns in the undifferentiated versus differentiated state were
identified, including (1) a set of genes that is consistently methyl-
ated in hiPSCs and hESCs and unmethylated in all examined
tissues, and (2) a group of genes that is methylated in hiPSCs
and hESCs and is unmethylated only in specific tissues. Anumber of genes known to be expressed in a cell-type-specific
manner belong to this latter group. Importantly, the lineage-
specific demethylation could be recapitulated by directed differ-
entiation, showing that developmental regulation of these genes
is preserved in hiPSCs. This observation supports the validity of
hiPSCs as models for development and disease and further
suggests that demethylation of genes has a prominent function
in differentiation. The large scope of this study also provided
a unique opportunity for comprehensive analyses of variation
between the hiPSC and hESC lines. A large set of genes was
found to be variably methylated among different hESCs and
hiPSCs, and this variable DNA methylation appeared to be
predominantly associated with imprinted genes and genes on
the X chromosome in female hiPSCs. Comparison of early and
late passage hiPSCs indicated that while some changes in
DNA methylation were likely results of the reprogramming
process, others could be attributed to continuous growth in
culture. Notably, specific culture methods seem to be associ-
ated with imprinting aberrations, such as hypermethylation of
DIRAS3, which could be linked to serum containing culture
media (Nazor et al., 2012). These findings are consistent with
earlier observations of gene- and clone-specific changes of
imprinting in hiPSCs (Pick et al., 2009). In addition, variable
DNA methylation was observed in female hiPSC and hESC lines
on X-linked genes that are unmethylated in male cells, thus re-
flecting the presence of an inactive X chromosome (Xi) in female
cells. Variation was largely due to a loss of DNA methylation of
X-linked genes that is associated with length in culture and
correlates with elevated expression of genes on the Xi and a
loss of XIST expression. These observations indicate that main-
tenance of XCI is compromised in female hiPSCs and hESCs at
later passages.
Instability of the Xi was also observed in a study investigating
female hiPSCs from patients with Lesch-Nyhan syndrome who
carry a mutation of HPRT on one of their X chromosomes
(Mekhoubad et al., 2012). In low-passage hiPSCs, inactivation
of one of the two X chromosomes was observed and was
derived from the Xi of the donor fibroblasts. Random XCI in the
donor cell population gives rise to two types of hiPSC lines
that express either the mutated or the intact HPRT gene, and
analyzing pairs of mutant and control hiPSCs can be useful forCell Stem Cell 11, July 6, 2012 ª2012 Elsevier Inc. 9
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same genetic background. However, after prolonged passage,
hiPSCs lose XIST expression, which was followed by reactiva-
tion of genes on the Xi. Reactivation of substantial portions if
not the entire Xi could be demonstrated in some hiPSC lines.
As a consequence HPRT expression was restored to heterozy-
gous levels in hiPSC lines that were initially HPRT deficient,
making these cells unsuitable for modeling Lesch-Nyhan syn-
drome. Importantly, neither differentiation nor further reprogram-
ming appeared to restore XIST expression or XCI. This finding
suggests that erosion of dosage compensation is a permanent
aberration in late-passage female hiPSCs.
In this issue of Cell Stem Cell, an independent study confirms
XIST expression and a cytologically distinct XCI in early-passage
hiPSCs (Anguerra et al., 2012). XIST expression is also observed
to be frequently lost upon prolonged culture, consistent with an
erosion of Xi silencing. Genome-wide expression profiling further
demonstrates that the expression of X-linked, but not auto-
somal, genes is frequently elevated in late-passage female
hiPSCs, which leads to expression profiles with signatures that
have been implicated in cancer. Specifically, loss of XIST
expression is correlated with upregulation of X-linked onco-
genes along with an accelerated growth rate in vitro (Anguerra
et al., 2012). Disruption of XCI is further associated with an
impaired differentiation potential. Taken together, these studies
show that erosion of DNA methylation and gene repression on
the Xi of female hiPSCs occurs during long-term culture and
affects diseasemodeling and differentiation potential. In addition
to female-specific aberrations in XCI, errors in imprinted gene
expression should now be considered in male and female
hiPSCs.
Tomoda et al. use a different culture system for re-
programming human cells (Tomoda et al., 2012). This system
is based on a proprietary medium and includes SNL feeder cells
(McMahon and Bradley, 1990) that express the cytokine LIF,
which is important for the culture of mouse ESCs. Female
hiPSCs derived under these conditions possess an Xi at early
passages, consistent with results of other studies (Anguerra
et al., 2012; Mekhoubad et al., 2012). However, the Xi is effi-
ciently reactivated upon further culture, and two active X chro-
mosomes are observed. In this study, Xi reactivation requires
LIF and is not observed in conditions where LIF or SNL feeder
cells are omitted. Reactivation of the Xi is accompanied by
a loss of XIST and higher expression of X-linked genes. Impor-
tantly, XCI is initiated and dosage compensation is restored
upon differentiation. This observation is important because it
shows that the epigenetic state of these cells differs from iPSCs
cultured in the other studies.
Different Developmental States of Human Pluripotent
Cells
All four studies agree on the point that early-passage hiPSCs
possess an Xi, thus reflecting maintenance of XCI from the
somatic donor cells. However, the dissimilarities reveal that
several different processes can lead to changes in epigenetic
characteristics, as observed by loss of Xi silencing. Whereas
Tomoda et al. observe that XCI is restored upon differentiation
of their hiPSCs, the other studies observe irreversible erosion
of dosage compensation (Anguerra et al., 2012; Mekhoubad10 Cell Stem Cell 11, July 6, 2012 ª2012 Elsevier Inc.et al., 2012; Nazor et al., 2012). These studies follow earlier
work that has led to conflicting observations. Studies of female
hiPSCs from RETT patients carrying a heterozygous X-linked
mutation in theMECP2 gene have observed either Xi reactivation
(Marchetto et al., 2010) or maintenance of XCI from the somatic
donor cells after reprogramming (Pomp et al., 2011). To reconcile
these differences it is helpful to consider findings from reprog-
ramming in the mouse. Mouse somatic cells can be re-
programmed into two different types of pluripotent stem cells,
corresponding to the preimplantation and postimplantation
embryo state (Han et al., 2011). Standard culture conditions for
hESCs are not conducive for mouse ESC culture but have
been used to derive a second pluripotent cell type from the
mouse postimplantation epiblast known as epiblast stem cells
(EpiSCs; Brons et al., 2007; Tesar et al., 2007). Mouse EpiSCs
have cell signaling and transcriptional characteristics similar to
hESCs. Notably, XCI is observed in female mouse EpiSCs,
whereas ESCs possess two active X chromosomes (Guo et al.,
2009). This has led to the proposal that mouse ESCs represent
an earlier developmental state commonly referred to as ground
state or naive pluripotency. This distinction is functionally rele-
vant as mouse ESCs, but not EpiSCs, have the potential to
contribute extensively to development of mice upon blastocyst
injection or tetraploid embryo complementation. In contrast
mouse EpiSCs can form a wide range of cell types in culture
but inefficiently contribute to development.
This raises the question of whether human pluripotent cells
with properties similar to mouse ESCs can be obtained. Several
reports have applied modified mouse ESC culture conditions for
establishing hESCs and hiPSCs with properties of mouse ESCs
(Buecker et al., 2010; Hanna et al., 2010; Lengner et al., 2010;
Wang et al., 2011b), albeit, ground state hiPSCs in some of these
studies were metastable (Buecker et al., 2010), required expres-
sion of additional factors (Wang et al., 2011b), or were limited in
passage (Hanna et al., 2010). These findings strongly suggest
that similar to the situation in the mouse, two distinct types of
human pluripotent stem cells might be cultured.
In hindsight, discrepancies on the XCI status of hiPSCs can
partly be reconciled by considering differences in culture condi-
tions. Loss of Xi gene silencing can result from either erosion of
dosage compensation or reactivation of the Xi due to capturing
a different pluripotent cell type (Figure 1). Similar to hiPSCs,
female hESCs vary in their XCI status and a useful classification
has been suggested (Silva et al., 2008). Class I hESCs possess
two active X chromosomes and lack XIST expression. Upon
differentiation, XIST expression is observed and XCI is initiated,
thus resembling properties of mouse ESCs indicative of ground
state pluripotency. Class II hESCs have initiated XCI and express
XIST. This class seems to correspond to early-passage hiPSC
cultures (Anguerra et al., 2012; Mekhoubad et al., 2012; Tchieu
et al., 2010; Tomoda et al., 2012). Class III hESCs are character-
ized by the presence of an Xi but have lost XIST expression.
Importantly, XCI is not initiated when class III hESCs are induced
to differentiate. These class III hESCs show similarities to late-
passage hiPSCs with irreversible erosion of dosage compensa-
tion (Anguerra et al., 2012; Mekhoubad et al., 2012; Nazor et al.,
2012). Depending on the choice of culture conditions, the ratio of
cells of the three classes can vary. In addition, cells of late-
passage class II or class III cultures do not appear to revert easily
Figure 1. Effect of Culture on XCI in Female hiPSCs
XCI is maintained from the somatic donor cell in early-passage hiPSCs. These
class II cells express XIST, and a cytologically distinct Xi can be detected.
Characteristics of the hiPSCs change upon further culture, depending on the
conditions. In the presence of LIF and feeder cells, Xi reactivation associated
with loss of XIST is observed. The resulting class I cells resemble aspects of
ground state pluripotency and will undergo random XCI upon differentiation.
Under standard culture condition loss of XIST and erosion of gene silencing on
the Xi (Xe) is observed. Erosion of dosage compensation is irreversible and XCI
is not initiated when these cells enter differentiation, similar to class III hESCs.
XIST expression is indicated in red text.
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2012). Heterogeneity of epigenetic states in ESC cultures has
also been observed in studies analyzing gene expression in
single cells (Hayashi et al., 2008; Hough et al., 2009). Taken
together, these data suggest that the culture history is an over-
arching factor for hiPSC characteristics.
The mouse system may provide further opportunities for
exploring certain aspects of the human reprogramming process.
Indeed, chemical inhibitors have been developed that facilitate
the conversion of mouse EpiSCs to ground state pluripotent
ESCs (Zhou et al., 2010). A recent study has further shown that
epigenetic disruptions during reprogramming of mouse iPSCs
can be prevented by ascorbic acid (Stadtfeld et al., 2012), which
is a cofactor for histone demethylases (Wang et al., 2011a). In
addition, the use of chemical inhibitors of histone deacetylases
has been shown to influence epigenetic properties of mouse
ESCs and hESCs (Hayashi et al., 2008; Ware et al., 2009). Impor-
tantly, these findings may be useful for obtaining hiPSCs that are
less prone to phenotypic drift and epigenetic aberrations.
Culture Conditions for hESCs and hiPSCs
It is possible that phenotypic drift in culture is an inherent prop-
erty of hESCs and hiPSCs. Alternatively, drift could be the result
of culture-induced mutations (Cheng et al., 2012) or reflect limi-
tations in culture conditions that could induce stress (Newman
and Cooper, 2010; Nishino et al., 2011; Pera and Tam, 2010).
The controversy over the endogenous state of XCI in hiPSCs
and hESC has provided information on culture conditions that
are either associated with XCI or not (Table 1). The study by
Tomoda et al. shows that LIF is critical for ground state pluripo-
tency in human cells (Tomoda et al., 2012). This finding has
important implications for the interpretation of earlier studies
that used conventional hiPSC culture conditions, which do not
include LIF, and thus might observe cells evolving along a
different trajectory (Anguerra et al., 2012; Nazor et al., 2012;
Tchieu et al., 2010). LIF is crucial for maintenance of mouse
and rat ESCs (Nichols and Smith, 2009). It is unclear how to in-
terpret studies that investigate potential class I hiPSC (XaXa)
maintenance in the absence of LIF in the culture medium. The
expectation would be that exit from ground state pluripotency
would be favored even if initially a sizeable population of class
I cells were present. LIF is used to derive pre-XCI hESCs in
low-oxygen conditions (Lengner et al., 2010). However, LIF is
not included in the study by Anguerra et al. (in their experiments
showing that the effect of low oxygen for Xi reactivation in
hiPSCs cannot be recapitulated; Anguerra et al., 2012). Although
this consideration cannot explain the discrepancy completely,
it might be helpful for reconciling the different observations.
Similarly, discrepant results on XCI in hiPSCs from RETT
syndrome patients could be the result of different culture condi-
tions (Marchetto et al., 2010; Pomp et al., 2011). Marchetto et al.
use proprietary media that might favor ground state pluripotent
hiPSCs, whereas Pomp et al. use standard hESC conditions.
Importantly, when previously reported culture conditions for in-
ducing ground state hiPSCs were applied (Hanna et al., 2010),
Pomp et al. also observed Xi reactivation and subsequent
random XCI in hiPSCs.
Adjusting the culture environment and reprogramming tech-
niques has great potential for further improvements in hiPSCCell Stem Cell 11, July 6, 2012 ª2012 Elsevier Inc. 11
Table 1. Selected Studies Examining either Ground State or EpiSC-like Human Pluripotent Cells
Pluripotent State Culture Conditions Properties Examined References
mESC-like ground state primate ESC medium (ReproCELL);
SNL feeders (STO line expressing mLIF);
4 ng/ml bFGF, 33 ng/ml IGF2
XaXa - > XaXi (dif); gene expression (Tomoda et al., 2012)
N2B27-based medium; MEF feeders;
hLIF, 10 mM forskolin; 3 mM CHIR99021,
1 mM PD0325901
XaXa - > XaXi (dif); Oct4 enhancer,
gene expression, GF response
(Hanna et al., 2010)
DMEM/F12; MEF feeders; hLIF, 15 ng/ml
hFGF2; FBS/KOSR/plasmonate;
physiological 4% oxygen
XaXa - > XaXi (dif); also XaXe
observed in this study
(Lengner et al., 2010)
mTeSR1 medium (StemCell Technologies)
Matrigel
XaXa - > XaXi (dif); MECP2 mutation (Marchetto et al., 2010)
DMEM/F12; STO feeder cells; hLIF,
20% KOSR; 5 mM CHIR99021, 1 mM
PD0325901
XaXa - > XaXi (dif); GF response (Wang et al., 2011b)
DMEM/F12; MEF feeders; 5 ng/ml bFGF,
20% KOSR (hLIF)
metastable hiPSCs;
transgene-dependent ground state
(Buecker et al., 2010)
mEpiSC-like human ESCs DMEM/F12; MEF feeders; 20 ng/ml FGF,
10% KOSR
XaXi and XaXe; gene expression (Anguerra et al., 2012)
standard conditions (FGF); MEF
feeders; + rescue with mTeSR medium
XaXi and XaXe (Mekhoubad et al., 2012)
DMEM/F12; MEF feeders; 20 ng/ml
bFGF, 20% KOSR
XaXi; gene expression (Tchieu et al., 2010)
KO-DMEM (Invitrogen); MEF feeders;
4 ng/ml bFGF, 20% KOSR
XaXi; MECP2 mutation; also validates
Hanna et al. protocol for Xi reactivation
(Pomp et al., 2011)
Details of culture conditions, experimental evidence, and literature references are given. KOSR, serum replacement (Invitrogen).
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components that correlate with ground state pluripotency or
Xi reactivation in hESCs and hiPSCs (Table 1; Figure 2). One
surprising observation is the use of LIF and FGF for hiPSC
culture, which have antagonistic effects on mouse ESCs
(Nichols and Smith, 2009). FGF is used for the culture of mouse
EpiSCs but has been linked to induction of differentiation of
mouse ESCs. FGF seems to be a growth or survival signal for
hiPSCs/hESCs and might at the same time induce EpiSC fate,
thus favoring exit from ground state pluripotency. High amounts
of FGF could result in EpiSC-like properties in hiPSCs, whereas
lower levels in combination with Igf2 or insulin might act as
a prosurvival and/or proliferation signal when differentiation is
inhibited by LIF (Tomoda et al., 2012). Furthermore, it is inter-
esting to note that LIF is not a complete substitute for SNL
feeders in the study by Tomoda et al. Feeders could potentially
contribute additional signals to maintain ground state pluripo-
tency. Ground state pluripotency of mouse and rat ESCs can
be maintained in the absence of feeders when MEK and
GSK3 kinase activity is inhibited by chemical compounds (Nich-
ols and Smith, 2009). These inhibitors have also been applied
for obtaining ground state pluripotent hiPSCs (Hanna et al.,
2010; Wang et al., 2011b). Notably, differences in FGF signaling
in mouse and human embryos have also been observed, sug-
gesting that species-specific differences might exist (Kuijk
et al., 2012; Roode et al., 2012). It will be interesting to deter-
mine if combinations of FGF and LIF with GSK3 and MEK inhi-
bition are useful for defining conditions for feeder-independent
hiPSC culture.12 Cell Stem Cell 11, July 6, 2012 ª2012 Elsevier Inc.Reprogramming Factor Expression
The stoichiometry and timing of expression of transcription
factors during reprogramming is also an important factor for
the characteristics of iPSCs. Suboptimal ratios in expression
levels of reprogramming factors have been linked to a loss of
imprinting at the Dlk1-Dio3 locus in mouse iPSCs and have
further been shown to compromise their ability to form all-
iPSC-derived mice (Carey et al., 2011). Recent findings also
suggest that additional reprogramming factors can lead to faster
and more efficient reprogramming (Wang et al., 2011b). Con-
versely, removal of reprogramming vectors after reprogramming
has been reported to enhance the differentiation potential of
iPSCs (Sommer et al., 2010). Modest expression of viral Klf4 is
observed in some hiPSC lines generated by Mekhoubad et al.
and might contribute to phenotypic drift (Mekhoubad et al.,
2012). This is consistent with the observed persistent differences
in gene expression signatures between hiPSCs and hESCs (Chin
et al., 2009). For avoiding mutations caused by the integration of
viral vectors, strategies for vector excision or the use of non-
integrating vectors can be considered. Tomoda et al. use an
episomal vector system for expressing reprogramming factors
that might contribute to improving the quality of hiPSCs for
disease modeling (Tomoda et al., 2012). However, vector inser-
tions cannot explain the variability that is observed among
hESC lines, suggesting that other factors are equally important.
X Inactivation in the Embryo and ESCs
One critical question is how similar ESC cultures are to the re-
lated cell types in the embryo. XCI has been studied extensively
Figure 2. Culture Conditions Associated with Ground State Human
Pluripotency
A number of studies have established hESCs and hiPSCs with properties
similar to mouse ESCs. FGF, insulin, and IGF2 are thought to enhance prolif-
eration, survival, and self-renewal of hESCs. The cytokine LIF activates the
JAK/STAT signaling pathway and induces transcription factors, including Klf4,
inmouse ESCs. A combination of chemical inhibitors of GSK3 (CHIR) andMEK
(PD03) kinase activity has been used to capture ground state pluripotency in
hiPSCs. MAPK signaling has been associated with differentiation. Inhibition of
GSK3 kinase activity by chemical inhibitors or WNT signaling leads to stabi-
lization of b-catenin (b-cat) that has been implicated in ESC self-renewal
through inactivation of TCF3 repressor function. In addition low oxygen levels
support ground state pluripotency of hESCs.
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mosome is initiated at the four-cell stage. The Xi is then reacti-
vated in the ICM of the blastocyst at E4.5 followed by initiation
of random XCI in the E5.5 embryo. Thus, mouse ESCs corre-
spond to the ICM and early epiblast, whereas EpiSCs might
represent features of postimplantation epiblast cells.
A recent study shows that XCI is not initiated in the human
embryo at the blastocyst stage (Okamoto et al., 2011). The re-
ported isolation of pre-XCI hESCs under low-oxygen conditions
is consistent with this observation (Lengner et al., 2010).
However, an earlier study had found that XCI is already initiated
in cleavage-stage human embryos (van den Berg et al., 2009).
These conflicting results are hard to reconcile and could point
to subtle differences in embryo culture or genetic variation.
Human preimplantation development takes longer and is more
complex than that of mice (reviewed in Niakan et al., 2012), sug-
gesting that the epigenetic states of cells at the blastocyst stage
might not be as clearly defined as in themouse (Kuijk et al., 2012;
Roode et al., 2012). Potentially, this could also contribute to the
variability of XCI in hESCs and hiPSCs.
Nazor et al. make the important observation that many genes
are methylated in hESCs and hiPSCs but are found in an unme-thylated state in tissues (Nazor et al., 2012). It is not clear if these
methylation patterns reflect the presumed developmental state
of hESCs. The current view is that DNA methylation is reduced
in the pluripotent cells of the embryo and increases upon further
development. This raises the question of whether culture-
induced hypermethylation could contribute to the observed
DNA methylation patterns in hiPSCs.
Conclusion and Future Outlook
Epigenetic aberrations have been noticed in earlier studies of
hiPSCs, but the implications for the application of hiPSCs re-
mained unclear (Panopoulos et al., 2011). The present studies
now demonstrate that epigenetic aberrations occur frequently
in hiPSCs and limit their use for disease modeling and potential
clinical applications. In particular, the reduced differentiation
potential and tumorgenicity induced by erosion of Xi silencing
in female hiPSCs is a concern for future applications of these
cells (Anguerra et al., 2012). A crucial question is what triggers
the phenotypic and epigenetic changes in hiPSCs. Loss of
XIST under standard hiPSC culture conditions is not easy to
explain but could be the result of stress-induced changes. This
view is supported by the observation that fibroblasts isolated
from RETT patients acquire a skewed XCI ratio before reprog-
ramming (Pomp et al., 2011), suggesting that culture stress is
a concern. Similar stress might be present in hiPSC cultures
but could be harder to detect. The identified instability and drift
in XCI and genomic imprinting might provide a sensitive readout
for further optimizing culture conditions.
It appears paramount to avoid epigenetic aberrations during
reprogramming and subsequent culture. Changing the develop-
mental state of hiPSC cultures might provide additional opportu-
nities to reach this aim. The use of FGF in standard hiPSC culture
conditions as a mitogen is likely to also induce an EpiSC-like
phenotype in hiPSCs. These cultures could be prone to drift
with progressive changes in DNA methylation and loss of XCI.
The hiPSC derivation by Tomoda et al. appears to lead to more
stable cultures. However, using SNL feeders is reminiscent of
the early mouse ESC culture before chemically defined condi-
tions became available. Increasing understanding of human
and mouse pluripotent states will facilitate the development of
chemically defined culture conditions that are a prerequisite for
clinical use of hiPSCs.
At the moment it remains unclear if ground state pluripotent
hiPSCs might be less exposed to epigenetic aberrations and
drift. The competence of ground state mouse and rat ESCs to
contribute to embryogenesis suggests that stable culture condi-
tions that maintain a well-preserved developmental potential
can be achieved (Nichols and Smith, 2009). However, compre-
hensive analysis of epigenetic and phenotypic properties of
ground state hiPSC lines will need to be confirmed in the future
using the genomic technologies as outlined in the study by Na-
zor et al. Notably, Tomoda et al. find that XCI is initiated when
their hiPSCs are differentiated into endodermal cells, but XIST
expression was not observed (Tomoda et al., 2012). This is
unusual because XIST expression is a marker for XCI in other
systems. This peculiarity might be linked to the particular choice
of differentiation protocol. Future investigation of other differen-
tiation protocols will be important especially because Hanna
et al. have shown that a shift to culture media with serum andCell Stem Cell 11, July 6, 2012 ª2012 Elsevier Inc. 13
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et al., 2010).
Maintaining XCI in female hiPSCs may be advantageous
for modeling X-linked disease such as RETT syndrome where
female patients are heterozygous for the disease-causing muta-
tion. It is conceivable that ground state hiPSCs could be
converted into neural stem cell cultures that have defined XCI
patterns to facilitate disease modeling. Understanding the
biology and characteristics of hiPSCs will certainly benefit future
clinical applications in regenerative medicine as well as research
into disease mechanism. Using powerful genomics technology
will provide the needed resolution to facilitate the development
of improved methods for reprogramming human cells.ACKNOWLEDGMENTS
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